Colorectal cancer (metastatic) - bevacizumab: evaluation report
Colorectal cancer (metastatic) - bevacizumab: evidence review group response
Colorectal cancer (metastatic) - bevacizumab: letter from the Department of Health
Colorectal cancer (metastatic) - bevacizumab: critique by the evidence review group of the additional analyses and amended model provided by the manufacturers
Colorectal cancer (metastatic) - bevacizumab: patient access scheme template submitted by Roche
Colorectal cancer (metastatic) - bevacizumab: PSA analysis submitted by Roche
Colorectal cancer (metastatic) - bevacizumab: response to ACD1 from consultees and commentators
This page was last updated: 19 August 2010
